Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis
German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...
Drug
Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China
Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...
Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...
Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine
China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...
111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...
Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment
China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205)...
Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New...
Biogen’s Aducanumab Administered to Chinese Patient for First Time
US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a...
Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos
Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use...